AMGN Apr 2020 190.000 call

OPR - OPR Delayed Price. Currency in USD
35.55
0.00 (0.00%)
As of 3:38PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close35.55
Open36.55
Bid0.00
Ask0.00
Strike190.00
Expire Date2020-04-17
Day's Range35.55 - 37.20
Contract RangeN/A
Volume82
Open InterestN/A
  • GlobeNewswire

    Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of pre-specified criteria for futility and superiority. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.

  • PR Newswire

    Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

    Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of pre-specified criteria for futility and superiority. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.

  • Amgen Stock Rises 3%
    Investing.com

    Amgen Stock Rises 3%

    Investing.com - Amgen (NASDAQ:AMGN) Stock rose by 3.01% to trade at $216.64 by 13:02 (18:02 GMT) on Wednesday on the NASDAQ exchange.

  • GuruFocus.com

    Berkshire Hathaway: No Urgency in the Urgent Zone

    Investors urgently need to go forward in their value disciplines at a time when value investing has rarely looked more valuable in the marketplace Continue reading...

  • Amgen Stock Falls 3%
    Investing.com

    Amgen Stock Falls 3%

    Investing.com - Amgen (NASDAQ:AMGN) Stock fell by 3.06% to trade at $211.27 by 14:18 (19:18 GMT) on Tuesday on the NASDAQ exchange.

  • Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock?
    Investor's Business Daily

    Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock?

    Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?

  • Reuters

    Drug pricing review group signs deal with Aetion for patient data

    The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly. Large national regulators, including the U.S. Food and Drug Administration and United Kingdom's National Institute for Health and Care Excellence (NICE), are considering increasing the use of data gathered outside of clinical trials on the effectiveness of treatments, often referred to as real-world data. The FDA is running a pilot project using Aetion's database of insurance claims to replicate clinical trial results, as part of a requirement to comply with healthcare legislation called the 21st Century Cures Act.

  • Would you tell your innermost secrets to Alexa? How AI therapists could save you time and money on mental health care
    MarketWatch

    Would you tell your innermost secrets to Alexa? How AI therapists could save you time and money on mental health care

    People reveal more personal and intimate details to human-like apps and bots that can ‘sense’ emotions and concerns.

  • Reuters

    Pharmaceutical companies develop system to better track counterfeit drugs

    Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co, have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday. Some two dozen companies in the industry including drugmakers, distributers, retailers and delivery firms created the blockchain-based MediLedger Network, which it has been testing in the verification of drug returns. Blockchain, which first emerged as the technology underlying virtual currency bitcoin, is a shared database maintained by a network of computers.

  • Nation’s largest insurer invests in Waltham healthcare AI startup
    American City Business Journals

    Nation’s largest insurer invests in Waltham healthcare AI startup

    A venture capital firm tied to the largest health insurer in the U.S., UnitedHealth Group, has invested in a local startup working to avoid unnecessary drug costs.

  • GuruFocus.com

    Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs

    Company’s shares up 70% just days after public offering Continue reading...

  • Bull of the Day: Guardant Health (GH)
    Zacks

    Bull of the Day: Guardant Health (GH)

    Bull of the Day: Guardant Health (GH)

  • Moody's

    Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured note offering of Amgen Inc. ("Amgen"). There are no changes to the existing ratings of Amgen including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating. Amgen's Baa1 rating reflects its position as the largest stand-alone biotechnology company, its high margins and its good cash flow.

  • MoneyShow

    Buckingham's Bets in Biotech

    John Buckingham is a value-oriented money manager and editor of the industry-leading advisory service, The Prudent Speculator. Here he reviews two recommended healthcare stocks -- both large cap players in the biotechnology sector.

  • Barrons.com

    Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy.

    In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.

  • Leaner, More Agile Teva Sees Brighter Days Ahead
    GuruFocus.com

    Leaner, More Agile Teva Sees Brighter Days Ahead

    Company has cut $3 billion in expenses and has high hopes for two key drugs Continue reading...

  • Reuters

    RPT-FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

    The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.

  • Coronavirus outbreak begins to disrupt booming China drug trials
    Reuters

    Coronavirus outbreak begins to disrupt booming China drug trials

    The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc. China has imposed a virtual lockdown on Wuhan and severely restricted travel in its wider province of Hubei and some other cities.

  • Buy AbbVie for its Growth Prospects, Yield and Low Valuation
    GuruFocus.com

    Buy AbbVie for its Growth Prospects, Yield and Low Valuation

    The company's Humira will lose patent protection soon, but its pipeline will more than offset the effects Continue reading...

  • Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
    Zacks

    Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

    Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

  • J&J Files Application for Darzalex Label Expansion With FDA
    Zacks

    J&J Files Application for Darzalex Label Expansion With FDA

    J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.

  • If You Had Bought Amgen (NASDAQ:AMGN) Shares Five Years Ago You'd Have Made 47%
    Simply Wall St.

    If You Had Bought Amgen (NASDAQ:AMGN) Shares Five Years Ago You'd Have Made 47%

    The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...

  • The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
    Zacks

    The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony

    The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony